These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25542597)

  • 1. Essential rules and requirements for global clinical trials in rare lung diseases: a sponsor's standpoint.
    Kuerner T
    Respir Investig; 2015 Jan; 53(1):2-6. PubMed ID: 25542597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
    Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
    Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical trials for children].
    Boos J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 May; 48(5):530-5. PubMed ID: 15887062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials in the Middle East and North Africa (MENA) Region: grandstanding or grandeur?
    Nair SC; Ibrahim H; Celentano DD
    Contemp Clin Trials; 2013 Nov; 36(2):704-10. PubMed ID: 23712082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of the development of medicines in idiopathic pulmonary fibrosis.
    Fregonese L; Eichler I
    BMC Med; 2015 Sep; 13():239. PubMed ID: 26399608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Academic investigator-initiated trials and the challenge of sponsor responsibility: the Cologne Sponsor Model.
    Georgias C; Grunow A; Olderog M; May A; Paulus U
    Clin Trials; 2012 Dec; 9(6):781-7. PubMed ID: 23104975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--chapter 1: Key ethical requirements and progress toward the definition of an international regulatory framework.
    Cozzi E; Tallacchini M; Flanagan EB; Pierson RN; Sykes M; Vanderpool HY
    Xenotransplantation; 2009; 16(4):203-14. PubMed ID: 19799760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idiopathic pulmonary fibrosis: recent trials and current drug therapy.
    Jones MG; Fletcher S; Richeldi L
    Respiration; 2013; 86(5):353-63. PubMed ID: 24296982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.
    King TE; Brown KK; Raghu G; du Bois RM; Lynch DA; Martinez F; Valeyre D; Leconte I; Morganti A; Roux S; Behr J
    Am J Respir Crit Care Med; 2011 Jul; 184(1):92-9. PubMed ID: 21474646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Operational aspect of participation in the multi-national clinical trials from the foreign pharmaceutical company's standpoint].
    Namazu K
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):328-30. PubMed ID: 17301556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Characteristics and management of idiopathic pulmonary fibrosis: INSIGHTS-IPF registry].
    Behr J; Hoeper MM; Kreuter M; Klotsche J; Wirtz H; Pittrow D
    Dtsch Med Wochenschr; 2012 Dec; 137(49):2586-8. PubMed ID: 23188642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug safety sciences and the bottleneck in drug development.
    Watkins PB
    Clin Pharmacol Ther; 2011 Jun; 89(6):788-90. PubMed ID: 21593756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Operation of a radiopharmacy for a clinical trial.
    Norenberg JP; Petry NA; Schwarz S
    Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical drug trials. Regulation, coordination and significance of "Good Clinical Practice"].
    Hvidberg EF
    Ugeskr Laeger; 1994 Feb; 156(6):789-93. PubMed ID: 8016980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New Japanese GCP--from the standpoint of a sponsor].
    Ebi O
    Gan To Kagaku Ryoho; 1998 Apr; 25(5):650-62. PubMed ID: 9571962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Examples of practice: clinical trials for medical devices and their application: wound care].
    Augustin M
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(5):347-53; discussion 353. PubMed ID: 22818157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.